45444 Federal Register / Vol. 83, No. 174 / Friday, September 7, 2018 / Notices 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: On August 

22, 2018 CDC published a notice in the 

Federal Register titled ‘‘Information 

Collection for Tuberculosis Data from 

Panel Physicians’’ (Vol. 83, No. 163 

Docket No. CDC–2018–0049, Pages 

42502–542503). This notice was 

published inadvertently. The notice is 

being withdrawn immediately for public 

comment. 

Jeffrey M. Zirger, 

Acting Chief, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–19383 Filed 9–6–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–18–0666; Docket No. CDC–2018– 

0042] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled National Healthcare Safety 

Network (NHSN). NHSN is a public 

health surveillance system that collects, 

analyzes, reports, and makes available 

data for monitoring, measuring, and 

responding to healthcare associated 

infections (HAIs), antimicrobial use and 

resistance, blood transfusion safety 

events, and the extent to which 

healthcare facilities adhere to infection 

prevention practices and antimicrobial 

stewardship. 

DATES: CDC must receive written 

comments on or before November 6, 

2018. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2018– 

0042 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Leroy A. 

Richardson, Information Collection 

Review Office, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, MS–D74, Atlanta, Georgia 

30329; phone: 404–639–7570; Email: 

omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

National Healthcare Safety Network 

(NHSN)—Revision—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

NHSN is a public health surveillance 

system that collects, analyzes, reports, 

and makes available data for 

monitoring, measuring, and responding 

to healthcare associated infections 

(HAIs), antimicrobial use and resistance, 

blood transfusion safety events, and the 

extent to which healthcare facilities 

adhere to infection prevention practices 

and antimicrobial stewardship. The data 

collected will be used to inform and 

detect changes in the epidemiology of 

adverse events resulting from new and 

current medical therapies and changing 

risks. NHSN is comprised of six 

components: Patient Safety, Healthcare 

Personnel Safety, Biovigilance, LongTerm Care Facility, Outpatient 

Procedure, and Dialysis. 

Changes were made to 33 data 

collection facility surveys with this new 

ICR. CDC revised three annual facility 

surveys for the Patient Safety 

component for Hospitals, Long-Term 

Acute Care Facilities, and Inpatient 

Rehabilitation Facilities. CDC’s 

revisions clarify the reporting 

requirements for the data collected on 

fungal testing, facility locations, and 

laboratory testing locations. 

Additionally, corresponding response 

options for these questions have been 

revised to include updated testing 

methods used by facilities to capture 

current HAI specific data specification 

requirements for NHSN. New required 

questions have been added to all Patient 

Safety component surveys. The new 

questions are designed to provide data 

on surveillance processes, policies, and 

standards that are used by reporting 

facilities to ensure that when an event 

is detected, the facility has the 

appropriate mechanism to conduct 

complete reporting. The Hospital 

Annual Survey added new required 

questions to provide data about neonatal 

antimicrobial stewardship practices 

because the focus of stewardship efforts 

in neonatology differ from the focus in 

adult and pediatric practice. Questions 

were removed and replaced on all three 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 174 / Friday, September 7, 2018 / Notices 45445 

Patient Safety surveys to align better 

with the Core Elements of Hospital 

Antibiotic Stewardship Programs 

specified by CDC. The Core Elements 

defined by CDC are part of broad-based 

efforts by CDC and its healthcare and 

public health partners to combat the 

threat of antibiotic-resistant bacteria. 

The new Antibiotic Stewardship 

Program questions will provide 

additional data about operational 

features of the programs that hospitals 

have implemented, which in turn will 

enable CDC and its healthcare and 

public health partners to target their 

efforts to help invigorate and extend 

antibiotic stewardship. 

CDC is introducing a new optional 

survey form that is designed to be 

completed by state and local health 

departments that participate in HAI 

surveillance and prevention activities. 

This new form will provide data on 

legal and regulatory requirements that 

are pertinent to HAI reporting. CDC 

plans to include data the health 

department survey in its annual 

National and State HealthcareAssociated Infection Progress Report. 

The report helps identify the progress in 

HAI surveillance and prevention at the 

state and national levels. Data about the 

extent to which state health 

departments have validated HAI data 

that healthcare facilities in their 

jurisdiction report to NHSN and the 

extent of state and local health 

department HAI reporting requirements 

are important data for users of CDC’s 

HAI Progress Report to consider when 

they are reviewing and interpreting data 

in the report. 

NHSN now includes a ventilatorassociated event available for NICU 

locations, which requires additional 

denominator reporting, in which CDC 

has provided an option to accommodate 

facilities that are reporting requested 

data by updating the corresponding 

surveys. The Pediatric VentilatorAssociated Event (PedVAE) was 

removed from the survey because a 

single algorithm is used to detect 

PedVAE events. 

NHSN has made updates to the 

Antimicrobial Use and Resistance 

(AUR) data collection tools for the 

purposes of monitoring additional 

microorganisms and their antimicrobial 

susceptibility profiles. Use of these 

updates in AUR surveillance will 

provide important additional data for 

clinical and public health responses to 

mounting antibiotic resistance 

problems. 

The Long-term Care Facility 

Component (LTCF) will be updating 

three forms, two of which will include 

an update for facilities to document the 

‘‘CDI treatment start’’ variable. Early CDI 

reporting data from nursing homes has 

shown exceptionally low event rates for 

many reporting facilities (e.g., zero 

events for six or more months). Since 

current CDI event detection is based on 

presence of a positive laboratory 

specimen, variability in the use of 

diagnostic testing as part of CDI 

management will have direct impact on 

the estimate of CDI burden in a facility 

(e.g., empiric treatment for CDI without 

confirmatory testing may result in the 

appearance of low disease burden). In 

order to determine whether low CDI 

event rates might be due to empiric CDI 

treatment practices, a new process 

measure will be incorporated into the 

monthly summary data on CDI for 

LTCFs. This measure, called ‘‘CDI 

treatment starts,’’ will allow providers 

to capture the number of residents 

started on antibiotic treatment for CDI 

that month based on clinical decisions 

(i.e., even those without a positive CDI 

test). This process measure should 

provide data on clinically-treated CDI in 

order to inform our understanding of 

CDI management practices and serve as 

a proxy for CDI burden in nursing 

homes. 

Overall, minor revisions have been 

made to a total of 33 forms within the 

package to clarify and/or update 

surveillance definitions, increase or 

decrease the number of reporting 

facilities, and add new forms. 

The previously approved NHSN 

package included 72 individual 

collection forms; the current revision 

request includes a total of 73 forms. The 

reporting burden will decrease by 

109,745 hours, for a total of 5,393,725 

hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Healthcare facility .... 57.100 NHSN Registration Form ............................ 2,000 1 5/60 167 

57.101 Facility Contact Information ........................ 2,000 1 10/60 333 

57.103 Patient Safety Component—Annual Hospital Survey.6,000 1 1.17 7,500 

57.105 Group Contact Information .......................... 1,000 1 5/60 83 

57.106 Patient Safety Monthly Reporting Plan ....... 6,000 12 15/60 18,000 

57.108 Primary Bloodstream Infection (BSI) .......... 6,000 44 33/60 145,200 

57.111 Pneumonia (PNEU) ..................................... 1,800 72 30/60 64,800 

57.112 Ventilator—Associated Event ...................... 6,000 144 28/60 403,200 

57.113 Pediatric Ventilator—Associated Event 

(PedVAE).

100 120 30/60 6,000 

57.114 Urinary Tract Infection (UTI) ....................... 6,000 40 20/60 80,000 

57.115 Custom Event .............................................. 600 91 35/60 31,850 

57.116 Denominators for Neonatal Intensive Care 

Unit (NICU).

6,000 12 4 288,000 

57.117 Denominators for Specialty Care Area 

(SCA)/Oncology (ONC).

2,000 9 5.03 90,600 

57.118 Denominators for Intensive Care Unit 

(ICU)/Other locations (not NICU or SCA).

6,000 60 5.03 1,812,000 

57.120 Surgical Site Infection (SSI) ........................ 6,000 36 35/60 126,000 

57.121 Denominator for Procedure ......................... 6,000 540 10/60 540,000 

57.122 HAI Progress Report State Health Department Survey.55 1 45/60 41 

57.123 Antimicrobial Use and Resistance (AUR)— 

Microbiology Data Electronic Upload Specification 

Tables.

1,000 12 5/60 1,000 


daltland on DSKBBV9HB2PROD with NOTICES
45446 Federal Register / Vol. 83, No. 174 / Friday, September 7, 2018 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

57.124 Antimicrobial Use and Resistance (AUR)— 

Pharmacy Data Electronic Upload Specification 

Tables.

2,000 12 5/60 2,000 

57.125 Central Line Insertion Practices Adherence 

Monitoring.

100 100 25/60 4,167 

57.126 MDRO or CDI Infection Form ..................... 6,000 72 30/60 216,000 

57.127 MDRO and CDI Prevention Process and 

Outcome Measures Monthly Monitoring.

6,000 24 15/60 36,000 

57.128 Laboratory-identified MDRO or CDI Event 6,000 240 20/60 480,000 

57.129 Adult Sepsis ................................................ 50 250 25/60 5,208 

57.137 Long-Term Care Facility Component—Annual Facility Survey.2,600 1 2 5,200 

57.138 Laboratory-identified MDRO or CDI Event 

for LTCF.

2,600 12 20/60 10,400 

57.139 MDRO and CDI Prevention Process Measures Monthly Monitoring for LTCF.2,600 12 20/60 10,400 

57.140 Urinary Tract Infection (UTI) for LTCF ........ 2,600 14 35/60 18,200 

57.141 Monthly Reporting Plan for LTCF ............... 2,600 12 5/60 2,600 

57.142 Denominators for LTCF Locations .............. 2,600 12 4.17 130,000 

57.143 Prevention Process Measures Monthly 

Monitoring for LTCF.

2,600 12 5/60 2,600 

57.150 LTAC Annual Survey .................................. 400 1 1.17 467 

57.151 Rehab Annual Survey ................................. 1,000 1 1.17 1,167 

57.200 Healthcare Personnel Safety Component 

Annual Facility Survey.

50 1 8 400 

57.203 Healthcare Personnel Safety Monthly Reporting Plan.19,500 1 5/60 1,625 

57.204 Healthcare Worker Demographic Data ....... 50 200 20/60 3,333 

57.205 Exposure to Blood/Body Fluids ................... 50 50 1 2,500 

57.206 Healthcare Worker Prophylaxis/Treatment 50 30 15/60 375 

57.207 Follow-Up Laboratory Testing ..................... 50 50 15/60 625 

57.210 Healthcare Worker Prophylaxis/Treatment—Influenza.50 50 10/60 417 

57.300 Hemovigilance Module Annual Survey ....... 500 1 1.42 708 

57.301 Hemovigilance Module Monthly Reporting 

Plan.

500 12 1/60 100 

57.303 Hemovigilance Module Monthly Reporting 

Denominators.

500 12 1.17 7,000 

57.305 Hemovigilance Incident ............................... 500 10 10/60 833 

57.306 Hemovigilance Module Annual Survey— 

Non-acute care facility.

200 1 35/60 117 

57.307 Hemovigilance Adverse Reaction—Acute 

Hemolytic Transfusion Reaction.

500 4 20/60 667 

57.308 Hemovigilance Adverse Reaction—Allergic 

Transfusion Reaction.

500 4 20/60 667 

57.309 Hemovigilance Adverse Reaction—Delayed 

Hemolytic Transfusion Reaction.

500 1 20/60 167 

57.310 Hemovigilance Adverse Reaction—Delayed 

Serologic Transfusion Reaction.

500 2 20/60 333 

57.311 Hemovigilance Adverse Reaction—Febrile 

Non-hemolytic Transfusion Reaction.

500 4 20/60 667 

57.312 Hemovigilance Adverse Reaction— 

Hypotensive Transfusion Reaction.

500 1 20/60 167 

57.313 Hemovigilance Adverse Reaction—Infection.500 1 20/60 167 

57.314 Hemovigilance Adverse Reaction—Post 

Transfusion Purpura.

500 1 20/60 167 

57.315 Hemovigilance Adverse Reaction—Transfusion Associated Dyspnea.500 1 20/60 167 

57.316 Hemovigilance Adverse Reaction—Transfusion Associated Graft vs. Host Disease.500 1 20/60 167 

57.317 Hemovigilance Adverse Reaction—Transfusion Related Acute Lung Injury.500 1 20/60 167 

57.318 Hemovigilance Adverse Reaction—Transfusion Associated Circulatory Overload.500 2 20/60 333 

57.319 Hemovigilance Adverse Reaction—Unknown Transfusion Reaction.500 1 20/60 167 

57.320 Hemovigilance Adverse Reaction—Other 

Transfusion Reaction.

500 1 20/60 167 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 174 / Friday, September 7, 2018 / Notices 45447 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

57.400 Outpatient Procedure Component—Annual 

Facility Survey.

5,000 1 10/60 417 

57.401 Outpatient Procedure Component—Monthly Reporting Plan.5,000 12 20/60 15,000 

57.402 Outpatient Procedure Component Same 

Day Outcome Measures.

1,200 25 40/60 20,000 

57.403 Outpatient Procedure Component—Monthly Denominators for Same Day Outcome Measures.1,200 12 40/60 9,600 

57.404 Outpatient Procedure Component—SSI 

Denominator.

5,000 540 10/60 450,000 

57.405 Outpatient Procedure Component—Surgical Site (SSI) Event.5,000 36 35/60 105,000 

57.500 Outpatient Dialysis Center Practices Survey.7,000 1 2.12 14,817 

57.501 Dialysis Monthly Reporting Plan ................. 7,000 12 5/60 7,000 

57.502 Dialysis Event .............................................. 7,000 60 25/60 175,000 

57.503 Denominator for Outpatient Dialysis ........... 7,000 12 10/60 14,000 

57.504 Prevention Process Measures Monthly 

Monitoring for Dialysis.

2,000 12 1.42 17,000 

57.505 Dialysis Patient Influenza Vaccination ........ 325 75 10/60 4,063 

57.506 Dialysis Patient Influenza Vaccination Denominator.325 5 10/60 271 

57.507 Home Dialysis Center Practices Survey ..... 350 1 30/60 175 

Total ................. .................................................................................... ........................ ........................ ........................ 5,393,725 

Jeffrey M. Zirger, 

Acting Chief, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of the Associate Director for Science, Office 

of the Director, Centers for Disease Control 

and Prevention. 

[FR Doc. 2018–19382 Filed 9–6–18; 8:45 am] 

BILLING CODE 4163–18–P?≤ 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Community Preventive 

Services Task Force (CPSTF) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) within 

the Department of Health and Human 

Services announces the next meeting of 

the Community Preventive Services 

Task Force (CPSTF) on October 17–18, 

2018, in Atlanta, Georgia. 

DATES: The meeting will be held on 

Wednesday, October 17, 2018, from 8:30 

a.m. to 6:00 p.m. EDT and Thursday, 

October 18, 2018, from 8:30 a.m. to 1:00 

p.m. EDT. 

ADDRESSES: The CPSTF Meeting will be 

held at the CDC Edward R. Roybal 

Campus, Centers for Disease Control 

and Prevention Headquarters (Building 

19), 1600 Clifton Road NE, Atlanta, GA 

30329. You should be aware that the 

meeting location is in a Federal 

government building; therefore, Federal 

security measures are applicable. For 

additional information, please see 

Roybal Campus Security Guidelines 

under SUPPLEMENTARY INFORMATION. 

Information regarding meeting logistics 

will be available on the Community 

Guide website (www.thecommunity

guide.org) closer to the date of the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Onslow Smith, Center for Surveillance, 

Epidemiology and Laboratory Services; 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

E–69, Atlanta, GA 30329, phone: (404) 

498–6778, email: CPSTF@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Meeting Accessibility: This spacelimited meeting is open to the public. 

All meeting attendees must register. To 

ensure completion of required security 

procedures and access to the CDC’s 

Global Communications Center, U.S. 

citizens intending to attend in person 

must register by October 10, 2018, and 

non-U.S. citizens intending to attend in 

person must register by September 19, 

2018. Failure to register by the dates 

identified could result in the inability to 

attend the CPSTF meeting in person. 

Those unable to attend the meeting in 

person are able to do so via Webcast. 

CDC will send the Webcast URL to 

registrants upon receipt of their 

registration. All meeting attendees must 

register by October 11, 2018 to receive 

the webcast information. CDC will email 

webcast information from the CPSTF@

cdc.gov mailbox. 

To register for the meeting, whether in 

person or via webcast, individuals 

should send an email to CPSTF@cdc.gov 

and include the following information: 

name, title, organization name, 

organization address, phone, email, and 

whether attending in person or via 

webcast. 

Public Comment: A public comment 

period, limited to three minutes per 

person, will follow the CPSTF’s 

discussion of each systematic review. 

Individuals wishing to make public 

comments must indicate their desire to 

do so with their registration by 

providing their name, organizational 

affiliation, and the topic to be addressed 

(if known). Public comments will 

become part of the meeting summary. 

Public comment is not possible via 

Webcast. 

Background on the CPSTF: The 

CPSTF is an independent, nonfederal 

panel whose members are appointed by 

the CDC Director. CPSTF members 


daltland on DSKBBV9HB2PROD with NOTICES